UK NHS Medicine Price Rises Needed to Retain Pharma Investment, Science Minister Says

Science minister Lord Patrick Vallance has stated that NHS medicine prices will need to rise to prevent further pharmaceutical investment leaving the UK, as major firms like Merck and AstraZeneca have paused or scrapped UK projects citing uncompetitive pricing and a difficult environment. Vallance acknowledged that the US, under President Donald Trump, exerts significant influence on global drug pricing, with higher prices in the US impacting the UK's position and creating tariff pressures. The UK government is engaged in ongoing discussions with the pharmaceutical industry and US counterparts to find a solution that balances investment incentives with patient benefits. Despite industry criticism of low UK drug prices and systemic barriers, companies like Moderna continue to invest heavily in UK research and development. Health Secretary Wes Streeting confirmed active negotiations between government departments and pharma firms to reach an agreement. Overall, Vallance emphasized that price increases are necessary for securing the future of pharmaceutical investment and benefiting NHS patients.